Regulatory requirements for marketing fixed dose combinations
The development of fixed-dose combinations (FDCs) is becoming increasingly important from a public health perspective. FDCs have advantages when there is an identifiable patient population for whom treatment with a particular combination of actives in a fixed ratio is safe and effective and when all...
Main Author: | B G Jayasheel |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2010-01-01
|
Series: | Perspectives in Clinical Research |
Subjects: | |
Online Access: | http://www.picronline.org/article.asp?issn=2229-3485;year=2010;volume=1;issue=4;spage=120;epage=123;aulast=Jayasheel |
Similar Items
-
Critical Analysis of Cardiovascular and Central Nervous System Fixed Dose Combinations Available in Indian Market
by: Krunal Prajapati, et al.
Published: (2016-12-01) -
Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials
by: Channing J. Paller, et al.
Published: (2019-06-01) -
Optimization of Hypertension Treatment using Fixed-Dose Combination of Perindropril/Amlodipine
by: Evan Hindoro, et al.
Published: (2015-12-01) -
Fixed‐dose combination therapy‐based protocol compared with free pill combination protocol: Results of a cluster randomized trial
by: Olutobi A. Sanuade, et al.
Published: (2023-02-01) -
India’s ban on antimicrobial fixed-dose combinations: winning the battle, losing the war?
by: Giorgia Sulis, et al.
Published: (2022-12-01)